Department of Surgery & Perioperative Care, University of Texas at Austin Dell Medical School, Austin, Texas.
Department of Urology, New York-Presbyterian Weill Cornell Medical Center, New York, New York, USA.
Curr Opin Urol. 2023 Jul 1;33(4):274-280. doi: 10.1097/MOU.0000000000001094. Epub 2023 Apr 4.
Robotic-assisted retroperitoneal lymph node dissection (R-RPLND) is an emerging surgical option for testicular cancer with less morbidity than open RPLND. We outline the operative technique used at our center and review contemporary evidence in the advancement of R-RPLND.
R-RPLND is being applied effectively beyond clinical stage I testicular cancer to treat low-volume, clinical stage II disease in both the primary and postchemotherapy setting. Compared with the open approach, R-RPLND offers shorter hospitalization and less blood loss with comparably low complications and oncologic control.
With ongoing adoption and optimization of R-RPLND, future studies will assess long-term oncologic outcomes and disseminate R-RPLND in the treatment of testicular cancer.
与开放式腹膜后淋巴结清扫术（R-RPLND）相比，机器人辅助的 R-RPLND 具有更低的发病率，是一种新兴的睾丸癌外科治疗选择。我们概述了我们中心使用的手术技术，并回顾了 R-RPLND 进展的当代证据。
R-RPLND 已成功应用于临床 I 期以外的睾丸癌，以治疗原发性和化疗后低容量临床 II 期疾病。与开放式手术相比，R-RPLND 具有较短的住院时间和较少的出血量，且并发症和肿瘤控制发生率相当低。
随着 R-RPLND 的不断采用和优化，未来的研究将评估长期肿瘤学结果，并将 R-RPLND 应用于睾丸癌的治疗。
